107 related articles for article (PubMed ID: 12114928)
1. PTEN mutation analysis in uterine leiomyosarcomas and mixed mullerian sarcomas.
Amant F; Vergote I
Am J Obstet Gynecol; 2002 Jul; 187(1):258. PubMed ID: 12114928
[No Abstract] [Full Text] [Related]
2. PTEN mutations in uterine sarcomas.
Amant F; de la Rey M; Dorfling CM; van der Walt L; Dreyer G; Dreyer L; Vergote I; Lindeque BG; Van Rensburg EJ
Gynecol Oncol; 2002 Apr; 85(1):165-9. PubMed ID: 11925138
[TBL] [Abstract][Full Text] [Related]
3. Mutational analysis of the PTEN gene in human uterine sarcomas.
Lancaster JM; Risinger JI; Carney ME; Barrett JC; Berchuck A
Am J Obstet Gynecol; 2001 May; 184(6):1051-3. PubMed ID: 11349153
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the c-myc proto-oncogene occurs frequently in uterine sarcomas.
Jeffers MD; Richmond JA; Macaulay EM
Mod Pathol; 1995 Sep; 8(7):701-4. PubMed ID: 8539225
[TBL] [Abstract][Full Text] [Related]
5. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus.
Nola M; Babić D; Ilić J; Marusić M; Uzarević B; Petrovecki M; Sabioncello A; Kovac D; Jukić S
Cancer; 1996 Dec; 78(12):2543-50. PubMed ID: 8952563
[TBL] [Abstract][Full Text] [Related]
6. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT.
Rushing RS; Shajahan S; Chendil D; Wilder JL; Pulliam J; Lee EY; Ueland FR; van Nagell JR; Ahmed MM; Lele SM
Gynecol Oncol; 2003 Oct; 91(1):9-14. PubMed ID: 14529657
[TBL] [Abstract][Full Text] [Related]
7. PTEN/MMAC1 gene mutation is a rare event in soft tissue sarcomas without specific balanced translocations.
Saito T; Oda Y; Kawaguchi K; Takahira T; Yamamoto H; Tamiya S; Tanaka K; Matsuda S; Sakamoto A; Iwamoto Y; Tsuneyoshi M
Int J Cancer; 2003 Mar; 104(2):175-8. PubMed ID: 12569572
[TBL] [Abstract][Full Text] [Related]
8. PTEN mutations are uncommon in Proteus syndrome.
Barker K; Martinez A; Wang R; Bevan S; Murday V; Shipley J; Houlston R; Harper J
J Med Genet; 2001 Jul; 38(7):480-1. PubMed ID: 11476065
[No Abstract] [Full Text] [Related]
9. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas.
Catasús L; Bussaglia E; Rodrguez I; Gallardo A; Pons C; Irving JA; Prat J
Hum Pathol; 2004 Nov; 35(11):1360-8. PubMed ID: 15668893
[TBL] [Abstract][Full Text] [Related]
10. Germline mutation of the tumour suppressor PTEN in Proteus syndrome.
Smith JM; Kirk EP; Theodosopoulos G; Marshall GM; Walker J; Rogers M; Field M; Brereton JJ; Marsh DJ
J Med Genet; 2002 Dec; 39(12):937-40. PubMed ID: 12471211
[No Abstract] [Full Text] [Related]
11. Dual Pten/Tp53 suppression promotes sarcoma progression by activating Notch signaling.
Guijarro MV; Dahiya S; Danielson LS; Segura MF; Vales-Lara FM; Menendez S; Popiolek D; Mittal K; Wei JJ; Zavadil J; Cordon-Cardo C; Pandolfi PP; Hernando E
Am J Pathol; 2013 Jun; 182(6):2015-27. PubMed ID: 23708211
[TBL] [Abstract][Full Text] [Related]
12. Role of p53 pathway alterations in uterine carcinosarcomas (malignant mixed Müllerian tumors).
Semczuk A; Ignatov A; Obrzut B; Reventos J; Rechberger T
Oncology; 2014; 87(4):193-204. PubMed ID: 25033979
[TBL] [Abstract][Full Text] [Related]
13. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis.
Jin Z; Ogata S; Tamura G; Katayama Y; Fukase M; Yajima M; Motoyama T
Int J Gynecol Pathol; 2003 Oct; 22(4):368-73. PubMed ID: 14501818
[TBL] [Abstract][Full Text] [Related]
14. Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.
Hensley ML; Chavan SS; Solit DB; Murali R; Soslow R; Chiang S; Jungbluth AA; Bandlamudi C; Srinivasan P; Tap WD; Rosenbaum E; Taylor BS; Donoghue MTA; Hyman DM
Clin Cancer Res; 2020 Jul; 26(14):3881-3888. PubMed ID: 32299819
[TBL] [Abstract][Full Text] [Related]
15. Mutational analysis of the PTEN/MMAC1 tumour suppressor gene in primary human malignant mesotheliomas.
Papp T; Schipper H; Pemsel H; Unverricht M; Muller KM; Wiethege T; Schiffmann D; Rahman Q
Oncol Rep; 2001; 8(6):1375-9. PubMed ID: 11605070
[TBL] [Abstract][Full Text] [Related]
16. [Characterization of TP53, APC, and PTEN mutational statuses of 120 human cancer cell lines by using yeast-based analyses].
Suzuki G
Hokkaido Igaku Zasshi; 2003 Sep; 78(5):437-49. PubMed ID: 14531287
[No Abstract] [Full Text] [Related]
17. Genetic and epigenetic alterations of the PTEN gene in soft tissue sarcomas.
Kawaguchi K; Oda Y; Saito T; Takahira T; Yamamoto H; Tamiya S; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2005 Apr; 36(4):357-63. PubMed ID: 15891996
[TBL] [Abstract][Full Text] [Related]
18. [PTEN/MMAC1 is apparently not a relevant tumor suppressor gene in development of hereditary breast carcinoma].
Estévez-Schwarz L; Grasmo-Wendler UH; Jandrig B; Scherneck S; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):273-5. PubMed ID: 14518258
[TBL] [Abstract][Full Text] [Related]
19. Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.
Burghaus S; Halmen S; Gass P; Mehlhorn G; Schrauder MG; Lux MP; Renner SP; Beckmann MW; Hein A; Thiel FC
Arch Gynecol Obstet; 2016 Aug; 294(2):343-51. PubMed ID: 26711836
[TBL] [Abstract][Full Text] [Related]
20. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome.
Pilarski R; Eng C
J Med Genet; 2004 May; 41(5):323-6. PubMed ID: 15121767
[No Abstract] [Full Text] [Related]
[Next] [New Search]
